Parexel Destroys Immune Systems, Not Liable

A reader writes: "The four TGN1412 test victims learned recently that they have no detectable t-cells, which makes it "likely" (read certain) they will suffer from numerous diseases and truncated lifespans. It has been determined that Parexel was negligent in its aftercare of the victims. The victims have already suffered severe injuries such as gangrene requiring the amputation of all toes and three fingers (without toes you cannot remain standing or walk, btw) and endured unimaginable agony. But it seems Parexel, despite having the moral responsibility for the outcome of its incompetence and the financial ability to pay proper restitution (estimated yearly revenue of $750 million) is ignoring the victims and using the legal system to avoid liability. The lessons are that $4000 is not worth risking your life over, that that is what you are doing if you are foolish enough to volunteer for medical testing whatever promises you receive not withstanding, and that if you are so foolish you will be left to die by the company responsible without legal recourse should things go wrong. In other words, only an ignorant would sign up for medical testing. I predict a decline in voluntary test subjects, and a rise in the use of prisoners and other 'disposable' human subjects."

Comments

Re:Send that to israel

[lawpoop]

Sean Connery, is that you?

Re:It's horrible, but

[Red Flayer]

Bah. It's Darwinism. Stupid enough to take the risk, stupid enough to get out of the gene pool. That company has done the human race a favor.

/saracasm.

I'm sure the reason why they're not isn't greed so much as a fear of litigation.

I think it's also to limit future liability... what happens if their next Stage 2 or Stage 3 research injures a bunch more people? We're talking several millions in medical expenses for each patient in this case. Setting a precedent like that is Bad News for big pharma and their stockholders.

Re:Evil is harming others for personal gain

[alfs boner]

You're disgusting.